Kristie Taylor
Vice President
Contact
KristieTaylor@westat.comOverview
Kristie Taylor, PhD, is a Vice President for Behavioral Health and Health Policy. Taylor’s expertise is in adult and youth tobacco use and cessation, environmental tobacco smoke exposure, and patterns of tobacco use.
Taylor is passionate about tobacco research because of the considerable harm combusted tobacco causes to people’s health and well-being. Despite reductions in tobacco use, it remains the leading cause of preventable death and disease, not just in the U.S. but around the world.
The tobacco research unit spans the areas of tobacco surveillance, epidemiology, tobacco use prevention and cessation, tobacco control program evaluation, biological research, and policy support. Clients include numerous federal, state, and international agencies, foundations, and academic institutions.
Education
- PhD, Sociology, University of Arizona
- MA, Sociology, University of Arizona
- BA (with high honors), Sociology, Eckerd College
Areas of Expertise
Behavioral Health Health Services Research and Health Policy Tobacco Survey Design-
Association between tobacco product use and asthma among US adults from the Population Assessment of Tobacco and Health (PATH) Study waves 2-4
10,
BMJ Open Respiratory Research
January 2023
M.F. Brunette, M.J. Halenar, K.C. Edwards, Kristie Taylor, J.A. Emond, S.E. Tanski, S. Woloshin, et al.
DOILink for: Association between tobacco product use and asthma among US adults from the Population Assessment of Tobacco and Health (PATH) Study waves 2-4 -
Author response to e-cigarettes and respiratory disorder: The broader research context
Nicotine and Tobacco Research
January 2023
J.D. Sargent, K.C. Edwards, J. Emond, S. Tanski, Kristie Taylor, J.P. Pierce, M.L. Goniewicz, et al.
DOILink for: Author response to e-cigarettes and respiratory disorder: The broader research context -
Using a medication event monitoring system to evaluate self-report and pill count for determining treatment completion with self-administered, once-weekly isoniazid and rifapentine
Contemporary Clinical Trials
January 2023
N.A. Scott, C. Sadowski, A. Vernon, B. Arevalo, K. Beer, A. Borisov, J.A. Cayla, et al.
DOILink for: Using a medication event monitoring system to evaluate self-report and pill count for determining treatment completion with self-administered, once-weekly isoniazid and rifapentine